Thus, combining drugs that inhibit function of EGFR/HER2 with dual PI3K/mTOR and MEK pathway inhibitors in order to abolish compensatory mechanisms may eliminate cancer cell survival and perhaps improve therapeutic effects in HER2-positive breast cancers [59-62]. The gene discussed is MAP2K7; the disease is breast carcinoma.